Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers Proxima, a cloud-based platform to store, analyze, and share spatial data; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI.[ Read More ]
The intrinsic value of one AKYA stock under the base case scenario is HIDDEN Compared to the current market price of 2.41 USD, Akoya Biosciences, Inc. is HIDDEN
Current Assets | 122 M |
Cash & Short-Term Investments | 83.1 M |
Receivables | 17 M |
Other Current Assets | 21.7 M |
Non-Current Assets | 58.6 M |
Long-Term Investments | 0 |
PP&E | 20.7 M |
Other Non-Current Assets | 37.9 M |
Current Liabilities | 35.3 M |
Accounts Payable | 11.8 M |
Short-Term Debt | 6.9 M |
Other Current Liabilities | 16.7 M |
Non-Current Liabilities | 91.3 M |
Long-Term Debt | 82.3 M |
Other Non-Current Liabilities | 9 M |
Revenue | 96.6 M |
Cost Of Revenue | 40.3 M |
Gross Profit | 56.3 M |
Operating Expenses | 104 M |
Operating Income | -57.7 M |
Other Expenses | 5.66 M |
Net Income | -63.3 M |
Net Income | -63.3 M |
Depreciation & Amortization | 8.89 M |
Capital Expenditures | -3.65 M |
Stock-Based Compensation | 10.4 M |
Change in Working Capital | -14.5 M |
Others | 5.6 M |
Free Cash Flow | -54.6 M |
Date | Value | Insider | Amount | Avg Price |
---|---|---|---|---|
5 months ago
Jun 11, 2024
|
Sell 15.6 K USD
|
McKelligon Brian
President and CEO |
- 7500
|
2.084 USD |
5 months ago
Jun 06, 2024
|
Sell 15.1 K USD
|
McKelligon Brian
President and CEO |
- 7500
|
2.0085 USD |
7 months ago
Mar 20, 2024
|
Sell 37.2 K USD
|
McKelligon Brian
President and CEO |
- 7500
|
4.9657 USD |
8 months ago
Mar 13, 2024
|
Sell 37 K USD
|
McKelligon Brian
President and CEO |
- 7500
|
4.939 USD |
8 months ago
Mar 13, 2024
|
Sell 37 K USD
|
McKelligon Brian
President and CEO |
- 7500
|
4.938 USD |
10 months ago
Dec 19, 2023
|
Sell 33.6 K USD
|
McKelligon Brian
President and CEO |
- 7500
|
4.4754 USD |
11 months ago
Dec 12, 2023
|
Sell 31.9 K USD
|
McKelligon Brian
President and CEO |
- 7500
|
4.2495 USD |
11 months ago
Nov 20, 2023
|
Sell 32.9 K USD
|
McKelligon Brian
President and CEO |
- 7500
|
4.3868 USD |
1 year ago
Sep 07, 2023
|
Bought 32.2 K USD
|
Pla Frederic
Chief Operating Officer |
+ 7000
|
4.6 USD |
1 year ago
Sep 07, 2023
|
Bought 59.8 K USD
|
Pla Frederic
Chief Operating Officer |
+ 13000
|
4.6011 USD |
1 year ago
Jun 12, 2023
|
Bought 100 K USD
|
Ek John Frederick
CFO |
+ 20000
|
5 USD |
1 year ago
Jun 12, 2023
|
Bought 100 K USD
|
LAI GOLDMAN MYLA
Director |
+ 20000
|
5 USD |
1 year ago
Jun 12, 2023
|
Bought 100 K USD
|
Mendel Scott
Director |
+ 20000
|
5 USD |
1 year ago
Jun 12, 2023
|
Bought 1.02 M USD
|
Winkler Matthew
Director |
+ 203388
|
5 USD |
1 year ago
Jun 12, 2023
|
Bought 600 K USD
|
SHEPLER ROBERT G
Director |
+ 120000
|
5 USD |
1 year ago
Jun 12, 2023
|
Bought 9.02 M USD
|
Raffin Thomas A.
Director |
+ 1803373
|
5 USD |
1 year ago
Jun 12, 2023
|
Bought 983 K USD
|
Raffin Thomas A.
Director |
+ 196627
|
5 USD |
1 year ago
Jun 12, 2023
|
Bought 100 K USD
|
Raffin Thomas A.
Director |
+ 20000
|
5 USD |
1 year ago
Jun 06, 2023
|
Sell 28.5 K USD
|
McKelligon Brian
President/CEO |
- 5000
|
5.7074 USD |
1 year ago
Dec 13, 2022
|
Sell 1.32 K USD
|
Nolan Garry Ph.D.
Director |
- 100
|
13.25 USD |
1 year ago
Mar 14, 2023
|
Sell 43.6 K USD
|
McKelligon Brian
President/CEO |
- 4774
|
9.135 USD |
1 year ago
Mar 14, 2023
|
Sell 2.24 K USD
|
McKelligon Brian
President/CEO |
- 226
|
9.918 USD |
1 year ago
Dec 13, 2022
|
Sell 926 K USD
|
SCHNETTLER THOMAS P
Director |
- 71050
|
13.03 USD |
1 year ago
Dec 14, 2022
|
Sell 182 K USD
|
DRISCOLL JOSEPH
Chief Financial Officer |
- 14574
|
12.455 USD |
2 years ago
Dec 13, 2021
|
Sell 1.32 K USD
|
Nolan Garry Ph.D.
Director |
- 100
|
13.25 USD |
1 year ago
Dec 06, 2022
|
Sell 60.4 K USD
|
McKelligon Brian
President/CEO |
- 5000
|
12.083 USD |
1 year ago
Dec 02, 2022
|
Sell 14.6 K USD
|
Nolan Garry Ph.D.
Director |
- 1100
|
13.25 USD |
1 year ago
Dec 01, 2022
|
Sell 66.8 K USD
|
Nolan Garry Ph.D.
Director |
- 5000
|
13.3576 USD |
2 years ago
Nov 16, 2022
|
Sell 3.98 K USD
|
Nolan Garry Ph.D.
Director |
- 300
|
13.2533 USD |
2 years ago
Nov 10, 2022
|
Sell 50.7 K USD
|
Nolan Garry Ph.D.
Director |
- 3810
|
13.3085 USD |
2 years ago
Nov 11, 2022
|
Sell 266 K USD
|
Nolan Garry Ph.D.
Director |
- 20000
|
13.2929 USD |
2 years ago
Nov 14, 2022
|
Sell 7.97 K USD
|
Nolan Garry Ph.D.
Director |
- 600
|
13.2767 USD |
2 years ago
Sep 14, 2022
|
Sell 110 K USD
|
Nolan Garry Ph.D.
Director |
- 8305
|
13.2552 USD |
2 years ago
Sep 09, 2022
|
Sell 295 K USD
|
Nolan Garry Ph.D.
Director |
- 22191
|
13.3089 USD |
2 years ago
Sep 12, 2022
|
Sell 23.9 K USD
|
Nolan Garry Ph.D.
Director |
- 1800
|
13.3023 USD |
2 years ago
Sep 07, 2022
|
Sell 64.2 K USD
|
McKelligon Brian
President/CEO |
- 5000
|
12.834 USD |
2 years ago
Jun 15, 2022
|
Sell 51.3 K USD
|
McKelligon Brian
President/CEO |
- 5000
|
10.252 USD |
2 years ago
Dec 09, 2021
|
Sell 317 K USD
|
Nolan Garry Ph.D.
Director |
- 25000
|
12.6705 USD |
2 years ago
Nov 22, 2021
|
Bought 328 K USD
|
Ramachandran Niro Ph.D
Chief Business Officer |
+ 25000
|
13.1317 USD |
2 years ago
Nov 19, 2021
|
Bought 938 USD
|
Ramachandran Niro Ph.D
Chief Business Officer |
+ 73
|
12.85 USD |
2 years ago
Nov 19, 2021
|
Bought 112 K USD
|
Mendel Scott
Director |
+ 8500
|
13.16 USD |
3 years ago
Nov 18, 2021
|
Bought 258 K USD
|
SHEPLER ROBERT G
Director |
+ 20000
|
12.925 USD |
3 years ago
Nov 18, 2021
|
Bought 183 K USD
|
SHEPLER ROBERT G
Director |
+ 15000
|
12.167 USD |